Linzess for irritable bowel syndrome with constipation (IBS-C) Linzess is approved to treat a digestive condition called irritable bowel syndrome with constipation (IBS-C)
Springer, Berlin pp 111147 Rennenberg H (1982) Glutathione metabolism and possible biological roles in higher-plants
Gastric emptying scintigraphy, wireless capsule motility testing, or breath testing quantifies your baseline delay severity
An update of the primary end point of RFS with a median follow-up 3.5 years showed an RFS rate of 59.8% (95% CI, 55.3%64.1%) in the pembrolizumab group versus 41.4% (95% CI, 39.2%48.8%) in the placebo group (HR, 0.59
You can find the full overview with usage and safety information in the Wegovy package leaflet
And of course, your weight should be optimized and ideally stable for six months to a year before surgery to ensure a consistent and enduring aesthetic outcome from surgery